Non-melanoma skin cancer

The Lancet

Volumn 375, Issue 9715, 2010, Pages 673-685

  Madan, Vishal ^a   Lear, John T ^a   Szeimies, Rolf Markus ^b  

^a HOPE HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIETHYL 3 HYDROXY 4 PYRIDONE; ALPHA2B INTERFERON; AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; ANTINEOPLASTIC AGENT; ARSENIC; CAPECITABINE; CIDOFOVIR; CYCLOPAMINE; DOBESILATE CALCIUM; FLUOROURACIL; GDC 0449; HISTONE DEACETYLASE INHIBITOR; IMIQUIMOD; INGENOL; INGENOL MEBUTATE; PHOTOSENSITIZING AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SOLASODINE; TAZAROTENE; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACTINIC KERATOSIS; ADD ON THERAPY; ALBINISM; APPLICATION SITE DESQUAMATION; APPLICATION SITE ERYTHEMA; APPLICATION SITE IRRITATION; APPLICATION SITE SWELLING; BASAL CELL CARCINOMA; BURNING SENSATION; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SUSCEPTIBILITY; CHEMOSURGERY; CIGARETTE SMOKING; CURETTAGE; DISEASE PREDISPOSITION; EDEMA; ENVIRONMENTAL FACTOR; ERYTHEMA; EXCISION; FEMALE; GENOTYPE; HISTOLOGY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERPIGMENTATION; HYPOPIGMENTATION; IONIZING RADIATION; KERATINOCYTE CARCINOMA; MALE; NON MELANOMA SKIN CANCER; NONMELANOMA SKIN CANCER; OCCUPATIONAL EXPOSURE; PATHOGENESIS; PHENOTYPE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; PUVA; REVIEW; RISK FACTOR; SEX DIFFERENCE; SIDE EFFECT; SKIN CANCER; SKIN CARCINOGENESIS; SKIN PIGMENTATION; SKIN ULCER; SOLAR RADIATION; SQUAMOUS CELL CARCINOMA; SUN EXPOSURE; TREATMENT INDICATION; TREATMENT OUTCOME; ULTRAVIOLET B RADIATION; WART VIRUS;

EID: 76749096684     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61196-X     Document Type: Review

References (155)

1. Diepgen T.L., and Mahler V. The epidemiology of skin cancer. Br J Dermatol 146 suppl 61 (2002) 1-6
2. Hoey S.E., Devereux C.E., Murray L., et al. Skin cancer trends in Northern Ireland and consequences for provision of dermatology services. Br J Dermatol 156 (2007) 1301-1307
3. Green A. Changing patterns in incidence of nonmelanoma skin cancer. Epithelial Cell Biol 1 (1992) 47-51
4. Glass A.G., and Hoover R.N. The emerging epidemic of melanoma and squamous cell skin cancer. JAMA 262 (1989) 2097-2100
5. Karagas M.R., and Greenberg E.R. Unresolved issues in the epidemiology of basal cell and squamous cell skin cancer. In: Mukhtar H. (Ed). Skin cancer: mechanisms and human relevance (1995), CRC Press, Boca Raton 79-86
6. American Cancer Society. Detailed guide: skin cancer-basal and squamous cell. http://www.cancer.org/docroot/CRI/content/CRI_2_4_1X_What_are_the_key_statistics_for_skin_cancer_51.asp?rnav=cri (accessed May 1, 2009).
7. Goodwin R.G., Holme S.A., and Roberts D.L. Variations in registration of skin cancer in the United Kingdom. Clin Exp Dermatol 29 (2004) 328-330
8. Cancer Research UK. CancerStats Key facts on skin cancer. How common is skin cancer?. http://info.cancerresearchuk.org/cancerstats/types/skin/#incidence (accessed May 1, 2009).
9. Holme S.A., Malinovszky K., and Roberts D.L. Changing trends in non-melanoma skin cancer in South Wales, 1988-98. Br J Dermatol 143 (2000) 1224-1229
10. Diffey B.L., and Langtry J.A. Skin cancer incidence and the ageing population. Br J Dermatol 153 (2005) 679-680
11. Katalinic A., Kunze U., and Schäfer T. Epidemiology of cutaneous melanoma and non-melanoma skin cancer in Schleswig-Holstein, Germany: incidence, clinical subtypes, tumour stages and localization (epidemiology of skin cancer). Br J Dermatol 149 (2003) 1200-1206
12. de Vries E., Louwman M., Bastiaens M., de Gruijl F., and Coebergh J.W. Rapid and continuous increases in incidence rates of basal cell carcinoma in the southeast Netherlands since 1973. J Invest Dermatol 123 (2004) 634-638
13. Staples M.P., Elwood M., Burton R.C., Williams J.L., Marks R., and Giles G.G. Non-melanoma skin cancer in Australia: the 2002 national survey and trends since 1985. Med J Aust 184 (2006) 6-10
14. Brewster D.H., Bhatti L.A., Inglis J.H., Nairn E.R., and Doherty V.R. Recent trends in incidence of nonmelanoma skin cancers in the East of Scotland, 1992-2003. Br J Dermatol 156 (2007) 1295-1300
15. Incidence of nonmelanoma skin cancer in New Brunswick, Canada, 1992 to 2001. J Cutan Med Surg 11 (2007) 45-52
16. Neale R.E., Davis M., Pandeya N., Whiteman D.C., and Green A.C. Basal cell carcinoma on the trunk is associated with excessive sun exposure. J Am Acad Dermatol 56 (2007) 380-386
17. English D.R., Armstrong B.K., Kricker A., and Fleming C. Sunlight and cancer. Cancer Causes Control 8 (1997) 271-283
18. Scotto J., Fears T.R., and Fraumeni Jr. J.F. Incidence of non-melanoma skin cancer in the United States. NIH Pub No 82-2433 (1983), US Department of Health and Human Services, Bethesda
19. Lim H.W., and Cooper K. The health impact of solar radiation and prevention strategies: report of the Environment Council, American Academy of Dermatology. J Am Acad Dermatol 41 (1999) 81-99
20. Kricker A., Armstrong B.K., English D.R., and Heenan P.J. A dose-response curve for sun exposure and basal cell carcinoma. Int J Cancer 60 (1995) 482-488
21. Kricker A., Armstrong B.K., English D.R., and Heenan P.J. Does intermittent sun exposure cause basal cell carcinoma? A case-control study in Western Australia. Int J Cancer 60 (1995) 489-494
22. Rosso S., Zanetti R., Martinez C., et al. The multicentre south European study "Helios" II: different sun exposure patterns in the aetiology of basal cell and squamous cell carcinomas of the skin. Br J Cancer 73 (1996) 1447-1454
23. Bastiaens M.T., Hoefnagel J.J., Bruijn J.A., Westendorp R.G., Vermeer B.J., and Bavinck J.B. Differences in age, site distribution, and sex between nodular and superficial basal cell carcinoma indicate different types of tumors. J Invest Dermatol 110 (1998) 880-884
24. Yu M., Zloty D., Cowan B., et al. Superficial, nodular, and morpheiform basal-cell carcinomas exhibit distinct gene expression profiles. J Invest Dermatol 128 (2008) 1797-1805
25. Rünger T.M. How different wavelengths of the ultraviolet spectrum contribute to skin carcinogenesis: the role of cellular damage responses. J Invest Dermatol 127 (2007) 2103-2105
26. Ridley A.J., Whiteside J.R., McMillan T.J., and Allinson S.L. Cellular and sub-cellular responses to UVA in relation to carcinogenesis. Int J Radiat Biol 85 (2009) 177-195
27. Lear J.T., Smith A.G., Strange R.C., and Fryer A.A. Detoxifying enzyme genotypes and susceptibility to cutaneous malignancy. Br J Dermatol 142 (2000) 8-15
28. Harwood C.A., Surentheran T., McGregor J.M., et al. Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals. J Med Virol 61 (2000) 289-297
29. Asgari M.M., Kiviat N.B., Critchlow C.W., et al. Detection of human papillomavirus DNA in cutaneous squamous cell carcinoma among immunocompetent individuals. J Invest Dermatol 128 (2008) 1409-1417
30. Shamanin V., zur Hausen H., and Lavergne D. Human papillomavirus infections in non melanoma skin cancers from renal transplant recipients and non immunosuppressed patients. J Natl Cancer Inst 88 (1996) 802-811
31. Karagas M.R., Nelson H.H., Sehr P., et al. Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin. J Natl Cancer Inst 98 (2006) 389-395
32. Bavinck J.B., Plasmeijer E.I., and Feltkamp M.C. Beta-papillomavirus infection and skin cancer. J Invest Dermatol 128 (2008) 1355-1358
33. Weinstock M.A., Coulter S., Bates J., et al. Human papillomavirus and widespread cutaneous carcinoma after PUVA photochemotherapy. Arch Dermatol 131 (1995) 701-704
34. Lindelof B., Sigurgeirsson B., Gabel H., et al. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol 143 (2000) 513-519
35. Moloney F.J., Comber H., Conlon P.J., et al. The role of immunosuppression in the pathogenesis of basal cell carcinoma. Br J Dermatol 154 (2006) 790-791
36. Moloney F.J., Comber H., O'Lorcain P., et al. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol 154 (2006) 498-504
37. Ho W.L., and Murphy G.M. Update on the pathogenesis of post-transplant skin cancer in renal transplant recipients. Br J Dermatol 158 (2008) 217-224
38. Wilkins K., Turner R., Dolev J.C., et al. Cutaneous malignancy and human immunodeficiency virus disease. J Am Acad Dermatol 54 (2006) 189-206
39. Otley C.C. Non-Hodgkin lymphoma and skin cancer: a dangerous combination. Australas J Dermatol 47 (2006) 231-236
40. Stern R.S., Liebman E.J., and Väkevä L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study. J Natl Cancer Inst 90 (1998) 1278-1284
41. Lindelöf B., Sigurgeirsson B., Tegner E., et al. PUVA and cancer: a large-scale epidemiological study. Lancet 338 (1991) 91-93
42. Karagas M.R., Stukel T.A., Umland V., et al. Reported use of photosensitizing medications and basal cell and squamous cell carcinoma of the skin: results of a population-based case-control study. J Invest Dermatol 127 (2007) 2901-2903
43. Man I., Crombie I.K., Dawe R.S., Ibbotson S.H., and Ferguson J. The photocarcinogenic risk of narrowband UVB (TL-01) phototherapy: early follow-up data. Br J Dermatol 152 (2005) 755-757
44. Lichter M.D., Karagas M.R., Mott L.A., et al. Therapeutic ionizing radiation and the incidence of basal cell carcinoma and squamous cell carcinoma. The New Hampshire Skin Cancer Study Group. Arch Dermatol 136 (2000) 1007-1011
45. Gawkrodger D.J. Occupational skin cancers. Occup Med (Lond) 54 (2004) 458-463
46. Marehbian J., Colt J.S., Baris D., et al. Occupation and keratinocyte cancer risk: a population-based case-control study. Cancer Causes Control 18 (2007) 895-908
47. Kennedy C., Bajdik C.D., Willemze R., and Bavinck J.B. Chemical exposures other than arsenic are probably not important risk factors for squamous cell carcinoma, basal cell carcinoma and malignant melanoma of the skin. Br J Dermatol 152 (2005) 194-197
48. Odenbro A., Bellocco R., Boffetta P., Lindelöf B., and Adami J. Tobacco smoking, snuff dipping and the risk of cutaneous squamous cell carcinoma: a nationwide cohort study in Sweden. Br J Cancer 92 (2005) 1326-1328
49. Hahn H., Wicking C., Zaphiropoulous P.G., et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 85 (1996) 841-851
50. Lear J.T., Hoban P., Strange R.C., and Fryer A.A. Basal cell carcinoma: from host response and polymorphic variants to tumour suppressor genes. Clin Exp Dermatol 30 (2005) 49-55
51. Marigo V., Davey R.A., Zuo Y., et al. Biochemical evidence that patched is the Hedgehog receptor. Nature 384 (1996) 176-179
52. Soufir N., Gerard B., Portela M., et al. PTCH mutations and deletions in patients with typical nevoid basal cell carcinoma syndrome and in patients with a suspected genetic predisposition to basal cell carcinoma: a French study. Br J Cancer 95 (2006) 548-553
53. Reifenberger J., Wolter M., Knobbe C.B., et al. Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br J Dermatol 152 (2005) 43-51
54. Brellier F., Valin A., Chevallier-Lagente O., et al. Ultraviolet responses of Gorlin syndrome primary skin cells. Br J Dermatol 159 (2008) 445-452
55. Danaee H., Karagas M.R., Kelsey K.T., et al. Allelic loss at Drosophila patched gene is highly prevalent in basal and squamous cell carcinomas of the skin. J Invest Dermatol 126 (2006) 1152-1158
56. Bastiaens M.T., ter Huurne J.A., Kielich C., et al. Melanocortin-1 receptor gene variants determine the risk of nonmelanoma skin cancer independently of fair skin and red hair. Am J Hum Genet 68 (2001) 884-894
57. Gudbjartsson D.F., Sulem P., Stacey S.N., et al. ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma. Nat Genet 40 (2008) 886-891
58. Kuerbitz S.J., Plunkett B.S., Walsh W.V., and Kastan M.B. Wild-type p5 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89 (1992) 7491-7495
59. Benjamin C.L., and Ananthaswamy H.N. p53 and the pathogenesis of skin cancer. Toxicol Appl Pharmacol 224 (2007) 241-248
60. Otto A.I., Riou L., Marionnet C., et al. Differential behaviors toward UVA and B radiation of fibroblasts and keratinocytes from normal and DNA repair deficient patients. Cancer Res 59 (1999) 1212-1218
61. Sands A.T., Abuin A., Sanchez A., Conti C.J., and Bradley A. High susceptibility to ultraviolet-induced carcinogenesis in mice lacking XPC. Nature 377 (1995) 162-165
62. Brash D.E. Roles of the transcription factor p53 in keratinocyte carcinomas. Br J Dermatol 154 suppl 1 (2006) 8-10
63. Demirkan N.C., Colakoglu N., and Duzcan E. Value of p53 protein in biological behavior of basal cell carcinoma and in normal epithelia adjacent to carcinomas. Pathol Oncol Res 6 (2000) 272-274
64. Soufir N., Ribojad M., Magnaldo T., et al. Germline and somatic mutations of the INK4a-ARF gene in a xeroderma pigmentosum group C patient. J Invest Dermatol 119 (2002) 1355-1360
65. Pacifico A., Goldberg L.H., Peris K., et al. Loss of CDKN2A and p14ARF expression occurs frequently in human nonmelanoma skin cancers. Br J Dermatol 158 (2008) 291-297
66. Lear J.T., Heagerty A., Smith A., et al. Multiple cutaneous basal cell carcinomas: Glutathione S-transferase (GSTM1, GSTT1) and cytochrome P450 (CYP2D6, CYP1A1) polymorphisms influence tumour numbers and accrual. Carcinogenesis 17 (1996) 1891-1896
67. Lear J.T., Smith A.G., Strange R.C., and Fryer A.A. Detoxifying enzyme genotypes and susceptibility to cutaneous malignancy. Br J Dermatol 142 (2000) 8-15
68. Ramachandran S., Fryer A.A., Smith A.G., et al. Basal cell carcinomas: association of allelic variants with a high-risk subgroup of patients with the multiple presentation phenotype. Pharmacogenetics 11 (2001) 247-254
69. Shay P.J.W., and Wright W.E. The reactivation of telomerase activity in cancer progression. Trends Genet 12 (1996) 129-131
70. Saleh S., Lam A.K.-Y., Gertraud B.P., et al. Telomerase activity of basal cell carcinoma in patients living in North Queensland, Australia. Hum Pathol 38 (2007) 1023-1029
71. Boldrini L., Loggini B., Gisfredi S., et al. Evaluation of telomerase in non-melanoma skin cancer. Int J Mol Med 11 (2003) 607-611
72. McCormack C.J., Kelly J.W., and Dorevitch A.P. Differences in age and body site distribution of the histological subtypes of basal cell carcinoma: a possible indicator of differing causes. Arch Dermatol 133 (1997) 593-596
73. Sexton M., Jones D.B., and Maloney M.E. Histologic pattern analysis of basal cell carcinoma. Study of a series of 1039 consecutive neoplasms. J Am Acad Dermatol 23 (1990) 1118-1126
74. Rippey J.J. Why classify basal cell carcinomas?. Histopathology 32 (1998) 393-398
75. Wong C.S., Strange R.C., and Lear J.T. Basal cell carcinoma. BMJ 327 (2003) 794-798
76. Newman J.C., and Leffell D.J. Correlation of embryonic fusion planes with the anatomical distribution of basal cell carcinoma. Dermatol Surg 33 (2007) 957-964
77. Wentzell J.M., and Wisco O.J. Embryologic fusion planes: a plea for more precise analysis. Dermatol Surg 34 (2008) 851-853
78. Ramachandran S., Fryer A., Smith A., Lear J., et al. Cutaneous basal cell carcinomas. Cancer 92 (2001) 354-358
79. Röwert-Huber J., Patel M.J., Forschner T., et al. Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol 156 (2007) 8-12
80. Marks R., Rennie G., and Selwood T.S. Malignant transformation of solar keratosis to squamous cell carcinoma. Lancet 331 (1998) 795-797
81. Glogau R.G. The risk of progression to invasive disease. J Am Acad Dermatol 42 1 Pt 2 (2000) 23-24
82. Salasche S.J. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 42 (2000) 4-7
83. Cox N.H., Eedy D.J., Morton C.A., Therapy Guidelines and Audit Subcommittee, and British Association of Dermatologists. Guidelines for management of Bowen's disease: 2006 update. Br J Dermatol 156 (2007) 11-21
84. Beham A., Regauer S., Soyer H.P., and Beham-Schmid C. Keratoacanthoma: a clinically distinct variant of well differentiated squamous cell carcinoma. Adv Anat Pathol 5 (1998) 269
85. Slater D.N., and McKee P.H. Minimum dataset for the histopathological reporting of common skin cancers (2002), The Royal College of Pathologists, London 1-23
86. Motley R., Kersey P., Lawrence C., and British Association of Dermatologists; British Association of Plastic Surgeons. Multiprofessional guidelines for the management of the patient with primary cutaneous squamous cell carcinoma. Br J Plast Surg 56 (2003) 85-91
87. Ulrich M., Stockfleth E., Roewert-Huber J., and Astner S. Noninvasive diagnostic tools for nonmelanoma skin cancer. Br J Dermatol 157 suppl 2 (2007) 56-58
88. Galletly N.P., McGinty J., Dunsby C., et al. Fluorescence lifetime imaging distinguishes basal cell carcinoma from surrounding uninvolved skin. Br J Dermatol 159 (2008) 152-161
89. Veness M.J. Defining patients with high-risk cutaneous squamous cell carcinoma. Australas J Dermatol 47 (2006) 28-33
90. Cherpelis B.S., Marcusen C., and Lang P.G. Prognostic factors for metastasis in squamous cell carcinoma of the skin. Dermatol Surg 28 (2002) 268-273
91. Brantsch K.D., Meisner C., Schönfisch B., et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol 9 (2008) 713-720
92. Drake L.A., Ceilley R.I., Cornelison R.L., et al. Guidelines for cutaneous squamous cell carcinoma. J Am Acad Dermatol 28 (1993) 289-292
93. McCord M.W., Mendenhall W.M., Parsons J.T., et al. Skin cancer of the head and neck with clinical perineural invasion. Int J Radiat Oncol Biol Phys 47 (2000) 89-93
94. Han A., and Ratner D. What is the role of adjuvant radiotherapy in the treatment of cutaneous squamous cell carcinoma with perineural invasion?. Cancer 109 (2007) 1053-1059
95. Chen J., Ruczinski I., and Jorgensen T.J. Nonmelanoma skin cancer and risk for subsequent malignancy. J Natl Cancer Inst 100 (2008) 1215-1222
96. Dinehart S.M., and Peterson S. Evaluation of the American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma and proposal of a new staging system. Dermatol Surg 31 (2005) 1379-1384
97. Veness M.J. Time to rethink TNM staging in cutaneous SCC. Lancet Oncol 9 (2008) 702-703
98. Telfer N.R., Colver G.B., Morton C.A., and British Association of Dermatologists. Guidelines for the management of basal cell carcinoma. Br J Dermatol 159 (2008) 35-48
99. Bath-Hextall F.J., Perkins W., Bong J., and Williams H.C. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev 24 (2007) CD003412.
100. Bath-Hextall F., Leonardi-Bee J., Somchand N., Webster A., Delitt J., and Perkins W. Interventions for preventing non-melanoma skin cancers in high-risk groups. Cochrane Database Syst Rev 4 (2007) CD005414.
101. Green A., Williams G., Neale R., et al. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet 354 (1999) 723-729
102. Cancer Research UK. About SunSmart. http://info.cancerresearchuk.org/healthyliving/sunsmart/about-sunsmart/?a=5441 (accessed May 1, 2009).
103. WHO. Ultraviolet radiation and the INTERSUN Programme. Sun protection: simple precautions in the sun. http://www.who.int/uv/sun_protection/en/ (accessed May 1, 2009).
104. National Collaborating Centre for Cancer. Improving outcomes for people with skin tumours including melanoma (2006), National Institute for Health and Clinical Excellence, London. http://www.nice.org.uk/nicemedia/pdf/CSG_Skin_Manual.pdf (accessed May 1, 2009).
105. Wolf D.J., and Zitelli J.A. Surgical margins for basal cell carcinoma. Arch Dermatol 123 (1987) 340-404
106. Walker P., and Hill D. Surgical treatment of basal cell carcinomas using standard postoperative histological assessment. Australas J Dermatol 47 (2006) 1-12
107. Griffiths R.W., Suvarna S.K., and Stone J. Do basal cell carcinomas recur after complete conventional surgical excision?. Br J Plast Surg 58 (2005) 795-805
108. Rowe D.E., Carroll R.J., and Day C.L. Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma. J Dermatol Surg Oncol 15 (1989) 424-431
109. Sterry W., and European Dermatology Forum Guideline Committee. Guidelines: the management of basal cell carcinoma. Eur J Dermatol 16 (2006) 467-475
110. Leibovitch I., Huilgol S.C., Selva D., et al. Basal cell carcinoma treated with Mohs surgery in Australia II. Outcome at 5-year follow-up. J Am Acad Dermatol 53 (2005) 452-457
111. Rowe D.E., Carroll R.J., and Day C.L. Prognostic factors for local recurrence, metastasis and survival rates in squamous cell carcinoma of the skin, ear and lip. J Am Acad Dermatol 26 (1992) 976-990
112. Chren M.M., Sahay A.P., Bertenthal D.S., Sen S., and Landefeld C.S. Quality-of-life outcomes of treatments for cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol 127 (2007) 1351-1357
113. Mosterd K., Krekels G., Nieman F.H.M., et al. Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up. Lancet Oncol 9 (2008) 1149-1156
114. Motley R.J., Gould D.J., Douglas W.S., and Simpson N.B. Treatment of basal cell carcinoma by dermatologists in the United Kingdom. British Association of Dermatologists Audit Subcommittee and the British Society for Dermatological Surgery. Br J Dermatol 132 (1995) 437-440
115. Rowe D.E., Carroll R.J., Day Jr. C.L., et al. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol 15 (1989) 315-328
116. Rodriguez-Vigil T., Vázquez-López F., and Perez-Oliva N. Recurrence rates of primary basal cell carcinoma in facial risk areas treated with curettage and electrodesiccation. J Am Acad Dermatol 56 (2007) 91-95
117. Mallon E., and Dawber R. Cryosurgery in the treatment of basal cell carcinoma. Assessment of one and two freeze-thaw cycle schedules. Dermatol Surg 22 (1996) 854-858
118. Thissen M., Nieman F., Ideler A., Berretty P., and Neumann H. Cosmetic results of cryosurgery versus surgical excision for primary uncomplicated basal cell carcinomas of the head and neck. Dermatol Surg 26 (2000) 759-764
119. Hall V., Leppard B., McGill J., et al. Treatment of basal-cell carcinoma: comparison of radiotherapy and cryotherapy. Clin Radiol 37 (1986) 33-34
120. Humphreys T.R., Malhotra R., Scharf M.J., et al. Treatment of superficial basal cell carcinoma and squamous cell carcinoma in situ with a high-energy pulsed carbon dioxide laser. Arch Dermatol 134 (1998) 1247-1252
121. Campolmi P., Brazzini B., Urso C., et al. Superpulsed CO2 laser treatment of basal cell carcinoma with intraoperatory histopathologic and cytologic examination. Dermatol Surg 28 (2002) 909-911
122. Campolmi P., Troiano M., Bonan P., Cannarozzo G., and Lotti T. Vascular based non-conventional dye laser treatment for basal cell carcinoma. Dermatol Ther 21 (2008) 402-405
123. Childers B.J., Goldwyn R.M., Ramos D., et al. Long-term results of irradiation for basal cell carcinoma of the skin of the nose. Plast Reconstr Surg 93 (1994) 1169-1173
124. Caccialanza M., Piccinno R., and Grammatica A. Radiotherapy of recurrent basal and squamous cell skin carcinomas: a study of 249 re-treated carcinomas in 229 patients. Eur J Dermatol 11 (2001) 25-28
125. Veness M.J. The important role of radiotherapy in patients with non-melanoma skin cancer and other cutaneous entities. J Med Imaging Radiat Oncol 52 (2008) 278-286
126. Avril M., Auperin A., Margulis A., et al. Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. Br J Cancer 76 (1997) 100-106
127. Petit J., Avril M., Margulis A., et al. Evaluation of cosmetic results of a randomised trial comparing surgery and radiotherapy in the treatment of basal cell carcinoma of the face. Plast Reconstr Surg 105 (2000) 2544-2551
128. Veness M.J., Morgan G.J., Palme C.E., and Gebski V. Surgery and adjuvant radiotherapy in patients with cutaneous head and neck squamous cell carcinoma metastatic to lymph nodes: combined treatment should be considered best practice. Laryngoscope 115 (2005) 870-875
129. Sedda A.F., Rossi G., Cipriani C., Carrozzo A.M., and Donati P. Dermatological high-dose-rate brachytherapy for the treatment of basal and squamous cell carcinoma. Clin Exp Dermatol 33 (2008) 745-749
130. Landthaler M., Hagspiel H.J., and Braun-Falco O. Late irradiation damage to the skin caused by soft X-ray radiation therapy of cutaneous tumors. Arch Dermatol 131 (1995) 182-186
131. Kleinerman R.A. Radiation-sensitive genetically susceptible pediatric sub-populations. Pediatr Radiol 39 (2009) S27-S31
132. Sloan K.B., Sherertz E.F., and McTiernan R.G. The effect of 5-fluorouracil on inhibition of epidermal DNA synthesis in vivo: a comparison of the effect of formulations and a prodrug of 5-FU. Arch Dermatol Res 282 (1990) 484-486
133. Gross K., Kircik L., and Kricorian G. 5% 5-Fluorouracil cream for the treatment of small superficial basal cell carcinoma: efficacy, tolerability, cosmetic outcome, and patient satisfaction. Dermatol Surg 33 (2007) 433-439
134. Reymann F. Treatment of basal cell carcinoma of the skin with 5-fluorouracil ointment. A 10-year follow-up study. Dermatologica 158 (1979) 368-372
135. Dummer R., Urosevic M., Kempf W., et al. Imiquimod in basal cell carcinoma: how does it work?. Br J Dermatol 149 suppl 66 (2003) 57-58
136. Geisse J., Caro I., Lindholm J., Golitz L., Stampone P., and Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 50 (2004) 722-733
137. Huber A., Huber J.D., Skinner Jr. R.B., et al. Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series. Dermatol Surg 30 (2004) 429-430
138. Gollnick H., Barona C.G., Frank R.G., et al. Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe. Eur J Dermatol 18 (2008) 677-682
139. Vidal D., Matías-Guiu X., and Alomar A. Fifty-five basal cell carcinomas treated with topical imiquimod: outcome at 5-year follow-up. Arch Dermatol 143 (2007) 266-268
140. Eigentler T.K., Kamin A., Weide B.M., et al. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. J Am Acad Dermatol 57 (2007) 616-621
141. Zeitouni N.C., Oseroff A.R., and Shieh S. Photodynamic therapy for non melanoma skin cancers. Mol Immunol 39 (2003) 1133-1136
142. Morton C.A., McKenna K.E., Rhodes L.E., and on behalf of the British Association of Dermatologists Therapy Guidelines and Audit Subcommittee and the British Photodermatology Group. Guidelines for topical photodynamic therapy: update. Br J Dermatol 159 (2008) 1245-1266
143. Kuijpers D., Thissen M.R., Thissen C.A., and Neumann M.H. Similar effectiveness of methyl aminolevulinate and 5-aminolevulinate in topical photodynamic therapy for nodular basal cell carcinoma. J Drugs Dermatol 5 (2006) 642-645
144. de Haas E.R., Kruijt B., Sterenborg H.J., et al. Fractionated illumination significantly improves the response of superficial basal cell carcinoma to aminolevulinic acid photodynamic therapy. J Invest Dermatol 126 (2006) 2679-2686
145. Soler A.M., Warloe T., Berner A., and Giercksky K.E. A follow-up study of recurrence and cosmesis in completely responding superficial and nodular basal cell carcinomas treated with methyl 5-aminolaevulinate-based photodynamic therapy alone and with prior curettage. Br J Dermatol 145 (2001) 467-471
146. Rhodes L.E., de Rie M.A., Leifsdottir R., et al. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol 143 (2007) 1131-1136
147. Mosterd K., Thissen M.R., Nelemans P., et al. Fractionated 5-aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial. Br J Dermatol 159 (2008) 864-870
148. Basset-Seguin N., Ibbotson S.H., Emtestam L., et al. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur J Dermatol 18 (2008) 547-553
149. Wilson B.D., Mang T.S., Stoll H., Jones C., Cooper M., and Dougherty T.J. Photodynamic therapy for the treatment of basal cell carcinoma. Arch Dermatol 28 (1992) 1597-1601
150. Madan V., Loncaster J.A., Allan D., et al. Systemic photodynamic therapy with Photofrin for naevoid basal cell carcinoma syndrome-A pilot study. Photodiagnosis Photodyn Ther 2 (2005) 273-281
151. Tucker S.B., Polasek J.W., Perri A.J., and Goldsmith E.A. Long-term follow-up of basal cell carcinomas treated with perilesional interferon alfa 2b as monotherapy. J Am Acad Dermatol 54 (2006) 1033-1038
152. Punjabi S., Cook L.J., Kersey P., Marks R., and Cerio R. Solasodine glycoalkaloids: a novel topical therapy for basal cell carcinoma. A double-blind, randomized, placebo-controlled, parallel group, multicenter study. Int J Dermatol 47 (2008) 78-82
153. Campbell S.M., Morton C.A., Alyahya R., et al. Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma. Br J Dermatol 159 (2008) 387-393
154. Szeimies R.M., and Karrer S. Towards a more specific therapy: targeting non-melanoma skin cancer cells. Br J Dermatol 154 suppl 1 (2006) 16-21
155. Liu C.Y. Fluorouracil for allergic reactions to capecitabine. Ann Pharmacother 36 (2002) 1897-1899